Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer

BACKGROUND: Trastuzumab improves outcomes in patients with HER2-overexpressing malignancies but is associated with decreases in left ventricular ejection fraction. Heart failure (HF) risks from other anti-HER2 therapies are less clear. OBJECTIVES: Using World Health Organization pharmacovigilance da...

Descripción completa

Detalles Bibliográficos
Autores principales: Waliany, Sarah, Caswell-Jin, Jennifer, Riaz, Fauzia, Myall, Nathaniel, Zhu, Han, Witteles, Ronald M., Neal, Joel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982216/
https://www.ncbi.nlm.nih.gov/pubmed/36875913
http://dx.doi.org/10.1016/j.jaccao.2022.09.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982216/
https://www.ncbi.nlm.nih.gov/pubmed/36875913
http://dx.doi.org/10.1016/j.jaccao.2022.09.007

Ejemplares similares